Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia

AimTo assess the clinical utility of FDG-PET as a diagnostic aid for differentiating Alzheimer’s disease (AD; both typical and atypical forms), dementia with Lewy bodies (DLB), frontotemporal lobar degeneration (FTLD), vascular dementia (VaD) and non-degenerative pseudodementia.MethodsA comprehensive literature search was conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted on six different diagnostic scenarios using the Delphi method.ResultsThe level of empirical study evidence for the use of FDG-PET was considered good for the discrimination of DLB and AD; fair for discriminating FTLD from AD; poor for atypical AD; and lacking for discriminating DLB from FTLD, AD from VaD, and for pseudodementia. Delphi voting led to consensus in all scenarios within two iterations. Panellists supported the use of FDG-PET for all PICOs—including those where study evidence was poor or lacking—based on its negative predictive value and on the assistance it provides when typical patterns of hypometabolism for a given diagnosis are observed.ConclusionAlthough there is an overall lack of evidence on which to base strong recommendations, it was generally concluded that FDG-PET has a diagnostic role in all scenarios. Prospective studies targeting diagnostically uncertain patients for assessing the added value of FDG-PET would be highly desirable.

[1]  R. Laforce,et al.  The Value of PET in Mild Cognitive Impairment, Typical and Atypical/Unclear Dementias: A Retrospective Memory Clinic Study , 2010, American journal of Alzheimer's disease and other dementias.

[2]  S. Goldman,et al.  Combined magnetic resonance imaging– and positron emission tomography–guided stereotactic biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients , 2000 .

[3]  Alan J. Thomas,et al.  Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.

[4]  Cindee M. Madison,et al.  Early 11C-PIB Frames and 18F-FDG PET Measures Are Comparable: A Study Validated in a Cohort of AD and FTLD Patients , 2011, The Journal of Nuclear Medicine.

[5]  H. Arai,et al.  Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies , 2012, Journal of the Neurological Sciences.

[6]  Koen Van Laere,et al.  EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[8]  Karl Herholz,et al.  18F-FDG PET and Perfusion SPECT in the Diagnosis of Alzheimer and Lewy Body Dementias , 2014, The Journal of Nuclear Medicine.

[9]  D. Loewenstein,et al.  Sensitivity and specificity of positron emission tomography and magnetic resonance imaging studies in Alzheimer's disease and multi-infarct dementia. , 1989, European neurology.

[10]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[11]  Clifford R. Jack,et al.  FDG PET and MRI in Logopenic Primary Progressive Aphasia versus Dementia of the Alzheimer’s Type , 2013, PloS one.

[12]  Max Wintermark,et al.  Recommendations for the Management of Cerebral and Cerebellar Infarction With Swelling: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2014, Stroke.

[13]  Frontal Network Syndrome Testing , 2013, American journal of Alzheimer's disease and other dementias.

[14]  J. Kornak,et al.  Amyloid Vs Fdg-pet in the Differential Diagnosis of Ad And , 2022 .

[15]  C. Weiller,et al.  Syndrome‐Specific Patterns of Regional Cerebral Glucose Metabolism in Posterior Cortical Atrophy in Comparison to Dementia with Lewy Bodies and Alzheimer's Disease—A [F‐18]‐Fdg Pet Study , 2013, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[16]  M. Fernández-Matarrubia,et al.  Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes , 2015, Journal of Neurology.

[17]  M. Freedman,et al.  Frontotemporal lobar degeneration , 1998, Neurology.

[18]  K. Ishii,et al.  Cerebral glucose metabolism in patients with frontotemporal dementia. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  G. Hajak,et al.  A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration , 2011, European Archives of Psychiatry and Clinical Neuroscience.

[20]  S. Cho,et al.  Subcortical Vascular versus Amnestic Mild Cognitive Impairment: Comparison of Cerebral Glucose Metabolism , 2009, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[21]  K. Ishii,et al.  Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer’s disease using FDG-PET and 3D-SSP , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  A. Drzezga,et al.  Metabolic Topology of Neurodegenerative Disorders: Influence of Cognitive and Motor Deficits , 2015, The Journal of Nuclear Medicine.

[23]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[24]  W. M. van der Flier,et al.  Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort , 2015, Dementia and Geriatric Cognitive Disorders.

[25]  J. Hatazawa,et al.  Can PET Data Differentiate Alzheimer's Disease from Vascular Dementia? , 2000, Annals of the New York Academy of Sciences.

[26]  Karl Herholz,et al.  18FDG PET in Vascular Dementia: Differentiation from Alzheimer's Disease Using Voxel-Based Multivariate Analysis , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  Luigi Gianolli,et al.  Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting , 2014, NeuroImage: Clinical.

[28]  S. Black,et al.  Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[29]  K. Ishii,et al.  Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB). , 1999, Neuroreport.

[30]  M. Brainin,et al.  Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2012 , 2004, European journal of neurology.

[31]  Karl J. Friston,et al.  A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia , 2014, Neuroinformatics.

[32]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[33]  A. Drzezga,et al.  Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  C. Rowe,et al.  The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-β-CIT SPECT for Diagnosis of Dementia with Lewy Bodies , 2009, Journal of Nuclear Medicine.

[35]  Nick C Fox,et al.  EFNS task force: the use of neuroimaging in the diagnosis of dementia , 2012, European journal of neurology.

[36]  A. Takeda,et al.  [18F]FDG-PET study in dementia with lewy bodies and alzheimer's disease , 2001, Progress in Neuro-psychopharmacology and Biological Psychiatry.

[37]  Satoshi Minoshima,et al.  Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation , 2001, Annals of neurology.

[38]  M. Hüll,et al.  Posterior cortical atrophy: variant of Alzheimer’s disease? , 2005, Journal of Neurology.

[39]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[40]  E. Huang,et al.  Nonfluent/Agrammatic PPA with In-Vivo Cortical Amyloidosis and Pick’s Disease Pathology , 2013, Behavioural neurology.

[41]  K. Leenders,et al.  Typical cerebral metabolic patterns in neurodegenerative brain diseases , 2010, Movement disorders : official journal of the Movement Disorder Society.

[42]  F Nobili,et al.  European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus , 2018, European journal of neurology.

[43]  J. Booij,et al.  Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[44]  H. Zaidi,et al.  Regions of Interest–Based Discriminant Analysis of DaTSCAN SPECT and FDG-PET for the Classification of Dementia , 2013, Clinical nuclear medicine.

[45]  G. Frisoni,et al.  Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[46]  V. Lowe,et al.  Clinical, FDG and amyloid PET imaging in posterior cortical atrophy , 2015, Journal of Neurology.

[47]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[48]  A. Drzezga,et al.  Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[49]  A. Drzezga,et al.  EANM-EAN recommendations for the use of brain 18 F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative cognitive impairment and dementia: Delphi consensus , 2018 .

[50]  G. Frisoni,et al.  Clinical utility of FDG-PET for the clinical diagnosis in MCI , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[51]  Stefano F. Cappa,et al.  Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia , 2014, NeuroImage: Clinical.

[52]  W. M. van der Flier,et al.  The Added Value of 18-Fluorodeoxyglucose-Positron Emission Tomography in the Diagnosis of the Behavioral Variant of Frontotemporal Dementia , 2014, American journal of Alzheimer's disease and other dementias.

[53]  Kenya Murase,et al.  Comparison of Regional Brain Volume and Glucose Metabolism Between Patients with Mild Dementia with Lewy Bodies and Those with Mild Alzheimer's Disease , 2007, Journal of Nuclear Medicine.

[54]  Nobuyuki Okamura,et al.  Glucose Hypometabolism and Neuropathological Correlates in Brains of Dementia with Lewy Bodies , 2000, Experimental Neurology.

[55]  J. O'Brien,et al.  An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy , 2016, British Journal of Psychiatry.

[56]  S. Gilman,et al.  11C-DTBZ and 18F-FDG PET measures in differentiating dementias. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[57]  Hiroaki Kazui,et al.  Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography , 1997, Neuroscience Letters.

[58]  S. Kushwaha,et al.  Differential Diagnosis of Neurodegenerative Dementias Using Metabolic Phenotypes on F-18 FDG PET/CT , 2014, The neuroradiology journal.

[59]  I. Lemahieu,et al.  Differential Regional Cerebral Uptake of 18F-Fluoro-2-Deoxy-D-Glucose in Alzheimer’s Disease and Frontotemporal Dementia at Initial Diagnosis , 2001, European Neurology.

[60]  O Sabri,et al.  Correlation of neuropsychological, morphological and functional (regional cerebral blood flow and glucose utilization) findings in cerebral microangiopathy. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[61]  J. Cummings,et al.  Dementia with Leukoaraiosis: Clinical Differentiation by Temporoparietal Hypometabolism on 18FDG-PET Imaging , 1999, Dementia and Geriatric Cognitive Disorders.

[62]  Gereon R. Fink,et al.  HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern , 1994, European Journal of Nuclear Medicine.

[63]  Karen M Rodrigue,et al.  Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.

[64]  K. Ishii,et al.  Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease , 1998, Neurology.

[65]  G. Frisoni,et al.  Assessing accuracy diagnostic FDG-PET studies to define clinical use for dementia diagnosis , 2018 .

[66]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[67]  R. Albin,et al.  Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease , 1996, Neurology.

[68]  D. Perani,et al.  Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[69]  W. Jagust,et al.  Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease. , 2008, Archives of neurology.

[70]  K. Herholz,et al.  Quantitative topographical EEG compared to FDG PET for classification of vascular and degenerative dementia. , 1994, Electroencephalography and clinical neurophysiology.

[71]  Cindee M. Madison,et al.  Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology , 2014, NeuroImage: Clinical.

[72]  P. Panegyres,et al.  Fluorodeoxyglucose-Positron Emission Tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study , 2009, BMC neurology.

[73]  T. Murakami,et al.  Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition , 2014, Annals of Nuclear Medicine.

[74]  A. Drzezga,et al.  Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[75]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[76]  Ignace Lemahieu,et al.  Positron emission tomography in vascular dementia , 1998, Journal of the Neurological Sciences.

[77]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[78]  Y. Hirayasu,et al.  Clinical profiles of dementia with Lewy bodies with and without Alzheimer's disease‐like hypometabolism , 2015, International journal of geriatric psychiatry.

[79]  I. McKeith,et al.  Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[80]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[81]  B. Boeve,et al.  Frontotemporal Dementia Mimicking Dementia With Lewy Bodies , 2008, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[82]  C. Jack,et al.  Elevated occipital β-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[83]  Murray Grossman,et al.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.

[84]  M. Brainin,et al.  Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004 * , 2004, European journal of neurology.

[85]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[86]  Nonfluent/Agrammatic PPA with In-Vivo Cortical Amyloidosis and Pick’s Disease Pathology , 2013, Behavioural neurology.

[87]  D. Perani,et al.  The Semantic Variant of Primary Progressive Aphasia: Clinical and Neuroimaging Evidence in Single Subjects , 2015, PloS one.

[88]  R. Laforce,et al.  Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes. , 2015, Journal of Alzheimer's disease : JAD.

[89]  S. Gilman,et al.  Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing , 2005, Experimental Neurology.

[90]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[91]  Michael Weiner,et al.  Effects of white matter lesions and lacunes on cortical function. , 2004, Archives of neurology.

[92]  K. Ishii,et al.  Occipital Glucose Metabolism in Dementia with Lewy Bodies with and without Parkinsonism: A Study Using Positron Emission Tomography , 2001, Dementia and Geriatric Cognitive Disorders.

[93]  V. Dhawan,et al.  Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography , 2013, Neuroradiology.

[94]  J. Cummings,et al.  Cortical Abnormalities Associated With Subcortical Lesions in Vascular Dementia: Clinical and Positron Emission Tomographic Findings , 1995 .

[95]  A. Mishra,et al.  Spectrum of neurocognitive dysfunction in Indian population on FDG PET/CT imaging , 2011, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India.